Search results

  1. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

  2. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  3. Chronic pain: oral ketamine (ESUOM27)

    Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

  4. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  5. Scleroderma: oral mycophenolate (ESUOM32)

    Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

  6. Gouty arthritis: canakinumab (ESNM23)

    Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

  7. Type 2 diabetes: lixisenatide (ESNM26)

    Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making